Literature DB >> 8260651

Transmembrane signaling by the interleukin-2 receptor: progress and conundrums.

G B Mills1, R Schmandt, S Gibson, B Leung, M Hill, C May, Y F Shi, D R Branch, L Radvanyi, K E Truitt.   

Abstract

Activation of the multicomponent interleukin-2 receptor (IL-2R) complex leads to a rapid increase in tyrosine phosphorylation of a number of cellular proteins including the IL-2R beta and IL-2R gamma chains of the IL-2R and the RAF-1 serine threonine kinase. In addition, phosphatidylinositol 3-kinase (PI-3K) protein and activity can be immunoprecipitated with anti-phosphotyrosine and anti-IL-2R beta antibodies from IL-2-activated but not resting T lymphocytes. We have demonstrated that the SH2 (SRC homology 2) domains of the 85 kDa subunit of PI-3K are sufficient to mediate binding of the PI-3K complex to tyrosine phosphorylated, but not non-phosphorylated IL-2R beta, suggesting that tyrosine phosphorylation is an integral component of the activation of PI-3K by the IL-2R. Since none of the members of the IL-2R complex contains an intrinsic tyrosine kinase domain, IL-2-induced tyrosine phosphorylation must be the consequence of activation of intracellular tyrosine kinases. SRC family members including lck, lyn and fyn have been demonstrated to associate with IL-2R beta through binding of the kinase domain to the acidic domain of IL-2R beta. However, we have demonstrated that the serine rich (SD) region of the cytosolic domain of IL-2R beta is also required for association of a tyrosine kinase with the IL-2R complex and that IL-2 can induce proliferation and tyrosine phosphorylation in cell lines which lack the known SRC family kinases expressed by T lymphocytes. Thus members of other kinase families besides SRC may also be involved in mediating IL-2 signal transduction. Biochemical studies and studies of cells expressing mutant IL-2 receptors indicate that IL-2-induced tyrosine kinase activation initiates a complex signaling cascade. The cascade includes SRC family kinase members such as lck, fyn, and lyn, activation of Raf-1 and PI-3K, and ras, and increased expression of the fos, fra-1, and jun protooncogenes. In addition, ligation of the IL-2R leads to rapid increases in myc expression and more delayed increases in the expression of the cdc2 and cdk2 kinases and the cyclins through a tyrosine phosphorylation independent pathway. Whether other biochemical processes initiated by IL-2R ligation, including activation of the MAP2, p70S6 and p90RSK serine threonine kinases, activation of NF-kappa B, and increased expression of Raf-1, Pim-1, bcl-2, IL-2R alpha and IL-2R beta, are consequences of the IL-2-induced tyrosine kinase cascade remains to be determined.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8260651     DOI: 10.1006/smim.1993.1041

Source DB:  PubMed          Journal:  Semin Immunol        ISSN: 1044-5323            Impact factor:   11.130


  4 in total

1.  Regulated expression of galectin-1 during T-cell activation involves Lck and Fyn kinases and signaling through MEK1/ERK, p38 MAP kinase and p70S6 kinase.

Authors:  Mercedes B Fuertes; Luciana L Molinero; Marta A Toscano; Juan M Ilarregui; Natalia Rubinstein; Leonardo Fainboim; Norberto W Zwirner; Gabriel A Rabinovich
Journal:  Mol Cell Biochem       Date:  2004-12       Impact factor: 3.396

Review 2.  IL-2 gene therapy of solid tumors: an approach for the prevention of signal transduction defects in T cells.

Authors:  K S Zier; B Gansbacher
Journal:  J Mol Med (Berl)       Date:  1996-03       Impact factor: 4.599

3.  Levels of serum-soluble receptor for interleukin-2 in patients with colorectal cancer.

Authors:  H Saito; S Tsujitani; K Katano; M Ikeguchi; M Maeta; N Kaibara
Journal:  Surg Today       Date:  1998       Impact factor: 2.549

4.  Serum tryptophan decrease correlates with immune activation and impaired quality of life in colorectal cancer.

Authors:  A Huang; D Fuchs; B Widner; C Glover; D C Henderson; T G Allen-Mersh
Journal:  Br J Cancer       Date:  2002-06-05       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.